Related Experiment Video

Updated: Feb 25, 2026

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.4K

Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in

Zeynep B Güngör1, Abdullah Tüten2, Hakan Ekmekçi1

  • 1a Department of Medical Biochemistry , Cerrahpasa Medical School, University of Istanbul , Istanbul , Turkey.

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|August 9, 2017
PubMed

Insights

Lipoprotein lipase-associated phospholipase A2 (Lp-PLA2) levels are elevated in preeclampsia (PE) and linked to future cardiovascular disease (CVD) risk. Genetic variations in PLA2G7 may increase CVD risk in women with PE.

Area of Science:

  • Cardiovascular Disease Research
  • Reproductive Health and Inflammation
  • Genetic Epidemiology

Background:

  • Lipoprotein lipase-associated phospholipase A2 (Lp-PLA2) is a key marker of vascular inflammation.
  • Preeclampsia (PE) is associated with heightened vascular inflammation and increased long-term cardiovascular disease (CVD) risk in women.
  • Genetic factors influencing vascular inflammation may predispose women with PE to future CVD.

Purpose of the Study:

  • To investigate the association between PLA2G7 gene polymorphisms, Lp-PLA2 levels, and cardiovascular risk factors in women with preeclampsia.
  • To determine if vascular inflammation-related genetic variations increase the risk of developing future cardiovascular disease in women with PE.

Main Methods:

  • A study involving 200 pregnant women, stratified into early-onset PE, late-onset PE, and control groups.
  • Measurement of serum Lp-PLA2 mass, activity, index, Hs-C-reactive protein (CRP), serum amyloid A (SAA), calprotectin, and PTX3 levels.
  • Analysis of PLA2G7 single-nucleotide polymorphisms (SNPs) rs1805017 and rs9381475 for correlation with Lp-PLA2 mass and logistic regression for risk assessment.

Main Results:

  • Serum Lp-PLA2 mass was significantly higher in both early and late PE groups compared to controls (p < 0.001).
  • Elevated levels of Lp-PLA2 index, Hs-CRP, SAA, calprotectin, and PTX3 were observed in PE groups (p < 0.001).
  • PLA2G7 SNPs rs1805017 and rs9381475 showed correlations with Lp-PLA2 mass in the early PE group, with carriers identified as an independent risk factor.

Conclusions:

  • Elevated Lp-PLA2 mass and specific PLA2G7 genetic variations are associated with preeclampsia.
  • These findings suggest that Lp-PLA2 genetic variability and elevated vascular inflammatory markers may contribute to the incidence of future cardiovascular events in women with a history of PE.
Abstract

Keywords:
Lp-PLA2 SNPLp-PLA2 massPTX3preeclampsiavascular inflammation

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
68
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
669
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27